FindTrial
Sign In

Pemetrexed + Cisplatin /Carboplatin

DRUG4 trials

Sponsors

Hutchison Medipharma Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd., Eikon Therapeutics

Conditions

Locally Advanced or Metastatic NSCLCNon Small Cell Lung Cancer (Squamous or Non Squamous)Non-Small Cell Lung CancerNon-small Cell Lung CancerStage 4 NSCLC

Phase 2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Not yet recruitingNCT07365319
Eikon TherapeuticsNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
Start: 2026-05-18End: 2040-12-31Target: 750Updated: 2026-01-26

Phase 3

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Active, not recruitingNCT05015608
Hutchison Medipharma LimitedNon-small Cell Lung Cancer
Start: 2021-11-22End: 2025-12-30Target: 250Updated: 2025-05-23
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
NCT06110663
Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-Small Cell Lung Cancer
Start: 2023-12-30End: 2025-02-28Target: 314Updated: 2023-11-01
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Not yet recruitingNCT07109531
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC
Start: 2025-08-31End: 2028-12-31Target: 286Updated: 2025-08-07

Related Papers

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
2026-01-13
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for <i>MET</i> Exon 14 Splice Site Mutated (<i>METex14+</i>) NSCLC Circa 2025.
2025-10-31
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and <i>MET</i> -amplification ( <i>MET</i> amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
Journal of Clinical Oncology2025-06-047 citations